Twenty-two newbie managers, fresh from B-schools across India, are raring to go. Only, they won’t make spreadsheets to sell soaps or fizzy drinks. From June, they will assist senior bureaucrats across 11 districts of Jharkhand where the Centre is funding uplift schemes. These managers — from IIT-Kharagpur, Tata Institute of Social Sciences (TISS)-Mumbai, Visva-Bharti in Bengal’s Santiniketan, XISS-Ranchi, XLRI-Jamshedpur and others — are Prime Minister’s Rural Development Fellows in some of...

The proposed criminalisation of consensual sex between youngsters in the 16-18 age group is seen as regressive and in denial of social realities. THE minimum age for consensual sex has been raised from 16 to 18 in the amended Protection of Children from Sexual Offences Bill, 2011, recently approved by the Union Cabinet. If approved by Parliament, this will make sexual activity with a person below 18 a criminal offence,...

As cartoons, like all other images, are constantly subject to fresh interpretation, there is a need to set boundaries within which dissent must be tolerated; or else we run the risk of damaging the task of knowledge building Like many books, works of art, and articles that have been summarily withdrawn from public circulation, for different political reasons, and due to public pressure, the controversial 1949 cartoon by Shankar has been...

Veteran agricultural scientist and alumnus of Harvard and Berkeley Universities, Dr Peter Kenmore was in Mumbai for NABARD’s 30th anniversary lecture on ‘Future of Global Agriculture: Challenges and Opportunities for India.’ This United Nations Food & Agriculture Organization India representative spoke to Yogesh Pawar on the current scenario in agriculture. Some excerpts: There’s a lot of churn over GM technology in India. At a time when the country is grappling with...

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...